Allergan plc Company Profile (NYSE:ACT)

Analyst Ratings

Consensus Ratings for Allergan plc (NYSE:ACT) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $270.00 (9.70% downside)

Analysts' Ratings History for Allergan plc (NYSE:ACT)
Show:
DateFirmActionRatingPrice TargetActions
3/28/2016Leerink SwannBoost Price TargetOutperform$180.00 -> $215.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015SusquehannaBoost Price TargetPositive$290.00 -> $325.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/4/2015Bank of America Corp.Set Price TargetBuy$350.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2015Raymond James Financial Inc.Initiated CoverageOutperform$344.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2015Deutsche Bank AGBoost Price TargetBuy$336.00 -> $343.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2015Canaccord GenuityReiterated RatingBuy$352.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/28/2015Citigroup Inc.Initiated CoverageFocus List -> Focus List$360.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2015GuggenheimSet Price TargetBuy$345.00 -> $355.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2015Barclays PLCSet Price TargetHold$300.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2015MizuhoInitiated CoverageBuy$358.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/8/2015Royal Bank Of CanadaReiterated RatingPositive$361.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2015Sterne Agee CRTReiterated RatingBuy$315.00 -> $340.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2015BMO Capital MarketsBoost Price TargetBuy$286.00 -> $373.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2015Goldman Sachs Group Inc.Initiated CoverageBuy$365.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2015JPMorgan Chase & Co.Initiated CoverageOverweight$310.00 -> $375.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/6/2015Edward JonesInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2015Sanford C. BernsteinBoost Price TargetOutperform$315.00 -> $350.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/20/2015ArgusBoost Price TargetBuy$310.00 -> $340.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2015CRT CapitalSet Price TargetBuy$288.00 -> $315.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2014Morgan StanleyBoost Price TargetOverweight$266.00 -> $315.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/4/2014Evercore ISIInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Allergan plc (NYSE:ACT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2015        
5/11/2015Q115$3.84$4.30$4.04 billion$4.23 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2015Q414$3.67$3.91$3.84 billion$4.01 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q314$3.10$3.19$3.63 billion$3.68 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q214$3.36$3.42$2.55 billion$2.67 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2014Q114$3.23$3.49$2.59 billion$2.66 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/20/2014Q413$3.05$3.17$2.68 billion$2.78 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2013Q313$2.09$2.09$2.04 billion$2.01 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013Q2 2013$2.00$2.01$1.99 billion$1.99 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013$1.86$1.99$1.97 billion$1.90 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2013Q4 2012$1.53$1.59$1.74 million$1.75 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Allergan plc (NYSE:ACT)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Allergan plc (NYSE:ACT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Allergan plc (NYSE:ACT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/9/2015Nesli BasgozDirectorSell2,200$297.89$655,358.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2014William MeuryInsiderSell4,550$269.14$1,224,587.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Albert Paonessa IIIInsiderSell6,642$230.49$1,530,914.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Albert HummelDirectorSell6,200$137.81$854,422.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2013George Fred WilkinsonInsiderSell16,749$138.00$2,311,362.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2013Jack MichelsonDirectorSell6,064$139.54$846,170.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2013David BuchenInsiderSell10,000$135.56$1,355,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2013Albert HummelDirectorSell40,000$134.44$5,377,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2013Paul BisaroCEOSell50,000$135.30$6,765,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2013Albert Paonessa IIIInsiderSell5,476$135.89$744,133.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013R Todd JoyceCFOSell15,000$137.98$2,069,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2013Albert HummelDirectorSell10,000$133.85$1,338,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2013Cathy KlemaDirectorSell1,667$133.03$221,761.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2013David BuchenInsiderSell17,000$133.03$2,261,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/9/2013Ronald TaylorDirectorSell5,000$135.14$675,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2013Charles EbertVPSell8,244$136.25$1,123,245.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2013Michel FeldmanDirectorSell10,000$136.94$1,369,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/2/2013Robert StewartInsiderSell14,564$136.02$1,980,995.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2013Charles M MayrInsiderSell1,000$91.77$91,770.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/12/2013Michael J FedidaDirectorSell8,000$89.00$712,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Allergan plc (NYSE:ACT)
DateHeadline
07/26/16 11:52 AMJerome Dodson Comments on Allergan -
07/26/16 11:41 AMJerome Dodson's Parnassus Fund 2nd Quarter Commentary -
07/26/16 11:09 AMCardiome Announces Pricing of Public Offering of 10000000 Common Shares - PR Newswire (press release)
07/25/16 07:45 PMCardiome Announces Proposed Public Offering of Common Shares - PharmiWeb.com (press release)
07/25/16 02:17 PMAllergan Receives Positive Opinion For Truberzi® (Eluxadoline) For ... - PR Newswire (press release)
07/25/16 07:03 AMTeva Canada Innovation Announces Approval of CINQAIR(TM) by Health Canada
07/24/16 07:03 AMAdamis Pharmaceuticals : Provides Update On License Agreement with Allergan plc
07/23/16 07:52 AMAstraZeneca's bid to save Crestor sales fails, court turns down IPR protection request till 2026 - domain-B
07/22/16 07:19 PMJudge Denies Order to Keep Generic Crestor Competitors Off the Market
07/22/16 02:17 PMAdamis Pharmaceuticals Provides Update On License Agreement with Allergan plc - Yahoo Finance
07/22/16 01:51 AMActual Experience Plc :ACT-GB: Earnings Analysis: For the six months ended March 31, 2016 : July 22, 2016 -
07/21/16 02:19 PMTeva Announces Pricing of Additional CHF1.0 Billion of Senior Notes in Connection with Pending Acquisition of ... - Business Wire (press release)
07/21/16 02:19 PMAdamis Pharmaceuticals Provides Update On License Agreement with Allergan plc - P&T Community
07/21/16 10:50 AMJudge Dismisses AstraZeneca’s Bid to Block Generic Crestor
07/21/16 10:50 AMAstraZeneca's bid to save Crestor sales fails, court turns down IPR protection request till 2026
07/20/16 09:10 PMJudge Dismisses AstraZeneca's Bid to Block Generic Crestor - TCTMD
07/20/16 09:10 PMTeva Announces Pricing of Additional €4.0 Billion of Senior Notes in Connection with Pending Acquisition of Actavis ... - Business Wire (press release)
07/20/16 02:31 PMWeitz Funds Comments on Allergan -
07/20/16 12:56 PMWeitz Funds' 2nd Quarter 2016 Value Fund Commentary -
07/20/16 10:26 AMTeva Announces Pricing of $15 Billion of Senior Notes in Connection with Pending Acquisition of Actavis Generics
07/20/16 10:26 AMAnti-inversion rules for U.S. companies will be challenged, Jones Day lawyer says at RNC panel
07/19/16 07:44 PMAnti-inversion rules for U.S. companies will be challenged, Jones Day lawyer says at RNC panel - cleveland.com
07/19/16 08:29 AMTeva Announces Pricing of $15 Billion of Senior Notes in Connection with Pending Acquisition of Actavis Generics - Business Wire (press release)
07/18/16 07:06 AMHC Stocks Zone: Mylan NV (NASDAQ:MYL) Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - share market updates (press release)
07/17/16 07:03 AMHyaluronic Acid Product Market – Global Industry Perspective, Comprehensive Analysis and Forecast, 2014 – 2020 - Medgadget (blog)
07/16/16 02:17 PMShire gets FDA nod for Xiidra (lifitegrast) for dry eye - ModernMedicine
07/15/16 06:32 PMForm 487 Advisors Disciplined - StreetInsider.com
07/15/16 06:32 PMTeva Said to Kick Off $22 Billion Bond Offering Backing Takeover - Bloomberg
07/14/16 11:53 AMTurns out nobody ever really wanted Bill Ackman at Valeant -
07/14/16 11:20 AMWhy Teva’s $20 Billion Bond Sale Makes Sense, as Long as It’s a Fixed Rate -
07/14/16 11:09 AMLongtime Valeant Investor Sequoia Fund Exits After Losses - Bloomberg
07/14/16 12:18 AMTeva Surges on Robust Outlook, Allergan Deal -
07/13/16 05:27 PMRuane Cunniff Comments on Allergan -
07/13/16 01:39 PMHi-Grade: Amid Welcoming Bond Market, Teva Eyes Acceleration of Actavis Financing - Forbes - Philly.comHi-Grade: Amid Welcoming Bond Market, Teva Eyes Acceleration of Actavis FinancingForbesTeva Pharmaceutical Industries today confirmed widespread market expectations that a much-anticipated blockbuster debt offering backing its $40.1 billion acquisition of Allergan's generics business, Actavis Generics, may be only days away. Teva CEO ...Welcome to the Hard Part, TevaBloombergTeva says Allergan deal to close 'any time', expects US antitrust clearanceReutersS&P Downgrades Teva Pharma (TEVA) to 'BBB'; Outlook is Stable (AGN)StreetInsider.comWall Street Journal -FiercePharma -Fortune -TheStreet.comall 61 news articles »
07/13/16 12:37 PMWelcome to the Hard Part, Teva -
07/13/16 12:02 PMUS STOCKS-Wall St record-setting rally peters out -
07/13/16 11:07 AMTeva Forecasts Growth After Expected Actavis Deal Closes -
07/13/16 10:21 AMTeva to Host Conference Call and Webcast to Provide Preliminary Outlook for 2016-2019 - Yahoo Finance
07/13/16 10:21 AMShire Surges After FDA Approves Xiidra for Dry-Eye Disease - Bloomberg
07/13/16 10:04 AMHow Will Recent Developments Affect Allergan? -
07/13/16 09:55 AMWhy the Teva Acquisition Proves It Is a Stock to Own for the Decade -
07/12/16 07:45 PMTeva to Host Conference Call and Webcast to Provide Preliminary Outlook for 2016-2019 - Business Wire (press release)
07/12/16 07:45 PMBernard Horn's Polaris Global Value Fund 2nd Quarter Letter - Yahoo Finance
07/12/16 02:17 PMBernard Horn's Polaris Global Value Fund —nd Quarter Letter - GuruFocus.com
07/12/16 02:17 PMRecent Trials Highlight DOJ's Challenges in Prosecuting Individuals for Corporate Misconduct - Lexology (registration)
07/12/16 12:24 PMAllergan Still Has More to Prove -
07/12/16 08:39 AMShire Stock Up As Eye Drug Wins Early Approval, Broad Label -
07/12/16 08:34 AM[$$] Shire boosted by FDA approval of dry eye drug - [at Financial Times] - The US drugs regulator has approved a new treatment for dry eyes made by Shire, putting the Anglo-Irish drugmaker in direct competition with Allergan, which makes the current bestseller. Roughly 16m US ...
07/12/16 08:07 AMHow Did Allergan’s International Brands Segment Perform? -
07/11/16 09:06 PMHow Did Allergan’s US Medical Aesthetics Segment Perform? -

Social

About Allergan plc

Allergan plc logoActavis, Inc. formerly Watson Pharmaceuticals, Inc., is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company also develops and out-licenses generic pharmaceutical products primarily in Europe through its Medis third-party business. The Company operates in three segments: Actavis Pharma, Actavis Specialty Brands and Anda Distribution. On January 23, 2013, the Company completed the acquisition of Uteron Pharma SA. On October 29, 2012, the Company sold its Rugby OTC pharmaceutical products and trademarks to The Harvard Drug Group, L.L.C. On January 24, 2012, the Company completed the acquisition of Ascent Pharmahealth Ltd.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: ACT
  • CUSIP: 00507K10
Key Metrics:
  • Previous Close: $299.00
  • 50 Day Moving Average: $297
  • 200 Day Moving Average: $285
  • P/E Ratio: N/A
  • P/E Growth: 0
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $18 EPS
  • Next Year EPS Consensus Estimate: $21 EPS
Additional Links:
Allergan plc (NYSE:ACT) Chart for Wednesday, July, 27, 2016